Disease Overview
Why Hepatitis B Cure Research Demands Specialized BRA
Hepatitis B functional cure programs combine novel mechanisms with overlapping hepatotoxicity profiles, while long-term nucleos(t)ide analogue therapy requires decades-long safety monitoring. The interplay of treatment-induced ALT flares, HBV reactivation risk, and complex virological endpoints demands specialized benefit-risk frameworks that traditional pharmacovigilance cannot adequately address.
Functional Cure Combination Toxicity
siRNA agents (JNJ-3989/VIR-2218) combined with capsid assembly inhibitors and PEG-IFN create overlapping hepatotoxicity risks. ALT flare management is critical as treatment-induced flares may indicate immune-mediated viral clearance or drug-induced liver injury. Distinguishing beneficial host immune response from toxicity requires sophisticated BRA models that integrate virological kinetics with liver safety biomarkers.
HBV Reactivation Risk
Immunosuppressive therapy-induced HBV reactivation remains a significant safety concern across oncology, rheumatology, and transplant settings. Checkpoint inhibitor-induced hepatitis flares in HBV-positive cancer patients add further complexity. Finite treatment duration strategies with nucleos(t)ide analogues require robust HBsAg monitoring frameworks to manage reactivation risk during and after treatment cessation.
Long-term NUC Safety
Over 20 years of continuous treatment with tenofovir disoproxil fumarate (TDF) raises cumulative renal toxicity (Fanconi syndrome, eGFR decline) and bone mineral density loss concerns. Tenofovir alafenamide (TAF) offers improved renal/bone profiles but with lipid elevations. Entecavir carries rare lactic acidosis risk. Treatment switching algorithms, pregnancy safety considerations (TDF vs. TAF), and resistance monitoring require comprehensive long-term BRA.
Platform Capabilities
How ArcaScience Addresses Hepatitis B BRA
Our modules are configured with HBV-specific clinical and real-world data, hepatotoxicity detection models trained on antiviral and functional cure patterns, and regulatory templates for infectious disease submissions.
HBV Clinical & Registry Data
1,800+ HBV clinical trials including functional cure combination studies, NUC long-term extension data, and finite treatment cessation trials. Integrated WHO Global Hepatitis Programme registry data, Asian-Pacific Association for the Study of the Liver (APASL) cohort data, and real-world evidence from endemic regions covering diverse HBV genotypes and co-infection patterns.
Explore Data Engine →ALT Flare & HBsAg Kinetics AI
AI models for ALT flare prediction and classification (immune-mediated clearance vs. drug-induced liver injury), HBsAg kinetics modeling for functional cure endpoint prediction, HBV reactivation risk stratification across immunosuppressive therapies, and NUC treatment switching decision support integrating renal function trajectories and bone density trends.
Explore AI Models →Antiviral & Cure Program Outputs
PSURs for long-term antiviral therapies with cumulative renal and bone safety analyses, functional cure program IND submissions with combination hepatotoxicity BRA, WHO prequalification dossiers for global access programs, and post-marketing commitment reports aligned with FDA, EMA, and PMDA hepatitis-specific regulatory guidance.
Explore Outputs →Hepatitis B Intelligence
Platform Performance in Hepatitis B
HBV pharmacovigilance data points
Faster hepatotoxicity signal detection
HBV-specific AI models
HBV regulatory submissions supported
Case Evidence — Hepatitis B
Functional Cure Combination Hepatotoxicity Signal Detection
Challenge
A pharma company developing a siRNA + capsid assembly inhibitor combination for HBV functional cure needed to differentiate treatment-induced ALT flares indicating beneficial immune clearance from drug-induced hepatotoxicity signals, while managing overlapping liver safety concerns from the multi-agent regimen.
Result
ArcaScience's AI models integrated ALT kinetics, HBsAg decline trajectories, and liver biomarker panels to classify ALT flares with high accuracy, enabling 3.5x faster characterization of flare etiology and a 38% reduction in false positive hepatotoxicity signals that would have triggered unnecessary dose modifications or treatment discontinuations.
Faster ALT flare characterization
Reduction in false positive hepatotoxicity signals
Head of Hepatology Safety
Global Pharma Company
Frequently Asked Questions